Clinical Trial Update: Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency [Phase 3]

View source ↗

Summary

Clinical trial update indicating that Ultragenyx's DTX301 AAV-mediated gene transfer for ornithine transcarbamylase deficiency is a Phase 3 study and currently …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ornithine Transcarbamylase Deficiency

Drugs mentioned

• DTX301

Snippet

Sponsor: Ultragenyx Pharmaceutical Inc | Conditions: OTC Deficiency | Phase 3 | Status: ACTIVE_NOT_RECRUITING